Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GIAPREZA vs ANGIOTENSIN ll ACETATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
A synthetic form of human angiotensin II, a vasoconstrictor that increases blood pressure by binding to angiotensin II type 1 receptors (AT1) on vascular smooth muscle, causing vasoconstriction.
Angiotensin II acetate is a synthetic peptide that acts as a potent vasoconstrictor by binding to the angiotensin II type 1 (AT1) receptor on vascular smooth muscle cells, leading to increased intracellular calcium and smooth muscle contraction. It also stimulates aldosterone secretion from the adrenal cortex, promoting sodium and water retention.
Increase blood pressure in adults with septic or other distributive shock
Treatment of hypotension in adults with septic or other distributive shock (FDA approved)
1 mg/kg/min IV continuous infusion, titrated to achieve target mean arterial pressure; maximum dose 10 mg/kg/min.
Intravenous infusion: 1-40 ng/kg/min titrated to achieve target blood pressure. Initial rate: 10 ng/kg/min.
Terminal elimination half-life is approximately 1 hour (range 0.5–2 hours); clinical context: requires continuous intravenous infusion for sustained vasopressor effect.
Terminal elimination half-life is approximately 30-60 minutes; clinical effect is short-lived requiring continuous intravenous infusion.
Metabolized by aminopeptidase A and angiotensin-converting enzyme (ACE) to smaller fragments, including angiotensin (1-8).
Primarily metabolized by aminopeptidases and other peptidases in plasma and tissues, with minimal hepatic involvement.
Primarily via proteolysis; renal excretion of unchanged drug is negligible (<1%). Fecal excretion is minimal.
Primarily renal (90-100%) as unchanged drug; minimal biliary/fecal elimination (<10%).
~70% bound to plasma proteins, primarily to albumin.
Approximately 30% bound to plasma proteins, primarily albumin.
Approximately 0.5 L/kg; indicates distribution primarily within extracellular fluid and plasma volume.
Approximately 0.3-0.5 L/kg; indicates distribution mainly in extracellular fluid.
Intravenous: 100% (only route of administration; oral bioavailability is negligible due to peptide degradation).
Intravenous: 100%; subcutaneous/intramuscular: not well absorbed due to rapid local metabolism; oral: negligible (<1%) due to extensive first-pass metabolism.
No dose adjustment required for renal impairment.
No specific dose adjustment required for renal impairment. Use caution in patients with renal artery stenosis.
No dose adjustment required for hepatic impairment.
No specific dose adjustment required for hepatic impairment.
Safety and efficacy not established; no FDA-approved pediatric dosing.
Intravenous infusion: 0.5-20 ng/kg/min titrated to effect. Safety and efficacy not established in neonates.
No specific adjustment recommended; use with caution due to potential cardiovascular comorbidities.
Start at lower end of dosing range (1-5 ng/kg/min) due to potential for decreased renal function and increased sensitivity.
No FDA black box warning.
No boxed warnings.
Thromboembolic events (venous and arterial) have been reported; monitor for signs of thrombosis.,Risk of adverse reactions from coadministration with ACE inhibitors (increased response) or angiotensin receptor blockers (increased response).,Concomitant use with vasopressors may require dose adjustment.,Not recommended for patients with high output states (e.g., cardiogenic shock) unless as a rescue therapy.
Thrombotic and thromboembolic events: Increased risk of venous and arterial thromboembolic events, including deep vein thrombosis, pulmonary embolism, and myocardial infarction.,Ischemic events: May cause cardiac ischemia and reduce cardiac output; use with caution in patients with coronary artery disease.,Vascular thrombosis: High risk of vascular thrombosis in patients with a history of thrombosis or hypercoagulable states.,Use in hypovolemia: Correct hypovolemia before administration to avoid exacerbation of vasoconstriction.,Pregnancy: May cause fetal harm; avoid use in pregnant women unless potential benefit outweighs risk.
No absolute contraindications identified.,Relative contraindications: patients with known hypersensitivity to any component; patients with a history of severe hypertension; patients with a known high risk of arterial or venous thrombosis.
Hypersensitivity to angiotensin II acetate or any component of the formulation,No absolute contraindications listed by the manufacturer; however, use is avoided in patients with uncorrected hypovolemia and those with a history of thromboembolic events.
No known food interactions. GIAPREZA is administered intravenously and does not interact with food.
No food interactions specific to angiotensin II acetate. Maintain a balanced diet as tolerated. Avoid excessive salt intake unless directed otherwise, as it may counteract the medication's effect on blood pressure.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental outcomes were observed at doses up to 2.1 times the maximum recommended human dose based on AUC. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: limited data; second and third trimesters: theoretical risk of fetal hypotension and hypoperfusion due to maternal hypotension.
First trimester: Potential for teratogenicity (increased risk of cardiovascular and CNS malformations). Second and third trimesters: Fetal hypotension, anuria, oligohydramnios, skull hypoplasia, pulmonary hypoplasia, and death. Use contraindicated in pregnancy.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. Consider developmental and health benefits of breastfeeding along with mother's clinical need for angiotensin II and any potential adverse effects on breastfed infant from drug or underlying maternal condition. M/P ratio not available.
No data on M/P ratio. Likely excreted in breast milk. Avoid breastfeeding due to unknown risks to neonate.
No specific dose adjustments recommended for pregnancy. Dose titration based on blood pressure response as in non-pregnant adults. Limited data on pharmacokinetic changes in pregnancy; consider potential increased volume of distribution and altered clearance, but no established dose modification.
No dose adjustment recommended if used; however, if inadvertently exposed, discontinue drug. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) may lower drug levels, but no established dose adjustment.
GIAPREZA (angiotensin II) is indicated for the treatment of refractory hypotension in adults with distributive shock who have failed adequate volume resuscitation and other vasopressors. Do not administer with angiotensin-converting enzyme (ACE) inhibitors due to risk of excessive hypotension. Monitor blood pressure continuously during administration. Prepare using strict aseptic technique; discard unused portion. Dosage is based on the patient's baseline mean arterial pressure (MAP) and response. Use with caution in patients with severe hypertension or conditions that may be exacerbated by vasoconstriction.
ANGIOTENSIN II ACETATE is a vasoconstrictor used for refractory hypotension in distributive shock. Administer via central line to avoid extravasation, which can cause severe tissue ischemia. Monitor blood pressure every 5 minutes during titration. Discontinue other vasopressors if possible to avoid additive arrhythmogenic effects. Use with caution in patients with coronary artery disease or previous myocardial infarction due to increased oxygen demand. Taper gradually to avoid rebound hypotension.
This medication is used to increase your blood pressure if it is dangerously low and not responding to other treatments.,Your blood pressure will be monitored continuously during the infusion.,Inform your healthcare provider if you have a history of high blood pressure, heart disease, or any allergies.,Do not stop or change the dose without consulting your doctor.,Report any symptoms such as chest pain, shortness of breath, or headache immediately.
This medication is given intravenously in the hospital to raise very low blood pressure. You will be closely monitored during treatment.,Inform your healthcare provider immediately if you experience chest pain, difficulty breathing, or irregular heartbeat.,Avoid sudden position changes to prevent dizziness, as blood pressure may fluctuate.,Report any pain, swelling, or color changes at the injection site, which could indicate medication leakage.,You may need regular blood tests to monitor kidney function and electrolyte levels.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GIAPREZA vs ANGIOTENSIN ll ACETATE, answered by our medical review team.
GIAPREZA is a Vasopressor that works by A synthetic form of human angiotensin II, a vasoconstrictor that increases blood pressure by binding to angiotensin II type 1 receptors (AT1) on vascular smooth muscle, causing vasoconstriction.. ANGIOTENSIN ll ACETATE is a Vasopressor that works by Angiotensin II acetate is a synthetic peptide that acts as a potent vasoconstrictor by binding to the angiotensin II type 1 (AT1) receptor on vascular smooth muscle cells, leading to increased intracellular calcium and smooth muscle contraction. It also stimulates aldosterone secretion from the adrenal cortex, promoting sodium and water retention.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GIAPREZA and ANGIOTENSIN ll ACETATE depend on the specific clinical indication. These are both Vasopressor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GIAPREZA is: 1 mg/kg/min IV continuous infusion, titrated to achieve target mean arterial pressure; maximum dose 10 mg/kg/min.. The standard adult dose of ANGIOTENSIN ll ACETATE is: Intravenous infusion: 1-40 ng/kg/min titrated to achieve target blood pressure. Initial rate: 10 ng/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GIAPREZA and ANGIOTENSIN ll ACETATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GIAPREZA is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental outcomes were observed at doses up to 2.1 times the maximum reco. ANGIOTENSIN ll ACETATE is classified as Category C. First trimester: Potential for teratogenicity (increased risk of cardiovascular and CNS malformations). Second and third trimesters: Fetal hypotension, anuria, oligohydramnios, sku. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.